Immunotherapy in aggressive B-cell lymphomas |
| |
| Institution: | 1. Leukemia and Myeloid Disorders Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, 9500 Euclid Avenue, Cleveland, OH 44195, USA;2. Tokyo Medical University, 6-1-1 Shinjuku, Shinjuku-ku, Tokyo 160-8402, Japan;3. Weill Cornell Medical College of Cornell University, 1300 York Ave, New York, NY 10065, USA;4. Huntsman Cancer Institute, University of Utah, 2000 Circle of Hope Dr, Salt Lake City, UT 84112, USA;5. Moores Cancer Center, University of California, San Diego, 3855 Health Sciences Dr, La Jolla, CA 92093, USA;6. UT Health San Antonio Cancer Center, 7979 Wurzbach Rd, San Antonio, TX 78229, USA;7. Columbia University Medical Center, 630 West 168th St, New York, NY 10032, USA;8. Juntendo University School of Medicine, 2-1-1, Hongo, Bunkyo-ku, Tokyo 113-8421, Japan;9. Division of Medical Oncology /Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan;10. Pfizer Inc, 235 East 42nd St, New York, NY 10017, USA;11. Pfizer Inc, 10555 Science Center Drive, San Diego, CA, 92121 USA;12. Pfizer Inc, 235 East 42nd St, New York, NY 10017, USA;13. Pfizer Inc, 235 East 42nd St, New York, NY 10017, USA;14. Pfizer Inc, 10555 Science Center Drive, San Diego, CA, 92121, United States;15. Pfizer Inc, 235 East 42nd St, New York, NY 10017, USA;p. Comprehensive Cancer Center, University of Michigan, 1500 East Medical Center Dr, Ann Arbor, MI 48109, USA;1. Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA;2. University of South Florida, Morsani College of Medicine, Tampa, FL, USA;1. Harvard Medical School, Boston, MA;2. Department of Internal Medicine, Brigham & Women’s Hospital, Boston, MA;3. Vanderbilt University Medical Center, Nashville, TN;4. Center for Hematologic Oncology, Dana-Farber Cancer Institute, Boston, MA;5. Bing Center for Waldenström’s Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA;6. Center for Cutaneous Oncology, Department of Dermatology, Dana-Farber/Brigham & Women’s Cancer Center, Boston, MA |
| |
| Abstract: | The idea that the immune system could be co-opted to treat cancer is not new; it has existed for centuries. However, what is new is the advancement of our understanding of how the immune system is regulated and how a tumor evolves to evade an immune response. This knowledge, combined with modern technologies to manipulate the immune system, both pharmacologically and genetically, has led to the realization of immuno-oncology as a new frontier in cancer therapeutics. This review will focus on pharmacologic immunotherapies in aggressive B cell lymphomas: checkpoint inhibition and bispecific antibodies. The success of checkpoint inhibitors in this heterogenous collection of diseases has largely been limited to those that genetic aberrations involving genes for checkpoint ligands, whereas bispecific antibodies appear to be more broadly efficacious but responses are short-lived. Investigation into the tumor microenvironment for each of the aggressive B cell lymphoma histologies, and interrogation of mechanisms of resistance as well as predictors of response to these immunotherapy approaches, will undoubtedly identify rational combinations as well as new therapeutic targets such that outcomes can be improved across these diseases. |
| |
| Keywords: | B-cell lymphoma Immunotherapy Checkpoint blockade Bispecific antibody |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
